TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01323231

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: XY-Zone
Description: The XY-Zone works to empower students to decrease risk factors and increase protective factors through three linear treatment steps. The first step is driven by guiding principles known as the five R's: respect, responsibility, relationship, role modeling, and reaching out. Through these principles, the participant explores healthy psychosocial behaviors and thoughts in a structured 10 session group setting. The leadership step builds upon the guiding principles and employs activities exploring true leadership through 10 sessions. During the leadership step, participants organize and carry out a service learning projects in their community. The third and final step is ambassador. Those in the ambassador step become a mentor to those in step one and are expected to explore the principles of leadership and the five R's, and determine their personal relevance to their lives as young men (Allen, 2009, p. i).
Study: NCT04380467

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D (cholecalciferol)
Description: (aviticol) 5x 20,000unit capsules administered monthly over 20 weeks
Study: NCT01296334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morphine LO
Description: intravenous infusion, 10 mg, once, 4 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine Hi
Description: intravenous infusion, 20 mg, once, 4 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine LO
Description: intravenous infusion, 0.3 mg, once, 4 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine Hi
Description: intravenous infusion, 0.6 mg, once, 4 hours

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: intravenous infusion, 0.9% saline, once, 4 hours
Study: NCT03278379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab will be administered intravenously as an infusion, at a dose of 10 milligram per kilogram once every 2 weeks, until occurence of progressive disease, unacceptable toxicity, or any of the other criteria for withdrawal listed in the protocol .
Study: NCT03014947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSB11022
Description: Subjects will receive single dose of 40 milligram (mg) MSB11022 as a subcutaneous injection in the lower abdomen on Day 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: US-licensed Humira
Description: Subject will receive single dose of 40 mg US-licensed Humira as a subcutaneous injection in the lower abdomen on Day 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EU-approved Humira
Description: Subject will receive single dose of 40 mg EU-approved Humira as a subcutaneous injection in the lower abdomen on Day 1.
Study: NCT04294329

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: US-guided Quadratus lumborum block.
Description: Performance of quadratus lumborum block using ultrasound machine to relieve pain after bariatric surgery

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: US-guided Quadratus lumborum block.
Description: Performance of quadratus lumborum block using ultrasound machine to relieve pain after bariatric surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Bupivacaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: normal saline
Study: NCT00974831

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amino Acid Drink Mixture
Description: 22 oz consumed in 7 oz, 8oz, 7 oz increments 5 minutes apart over 15 mins

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Glucose drink
Description: 22 oz consumed in 7 oz, 8oz, 7 oz increments 5 minutes apart over 15 mins
Study: NCT02927340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Study: NCT01552824

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CYSTO
Description: Fetal cystoscopy will be performed by introducing a 2.2mm sheath with 1.0mm fetoscope into fetal bladder under ultrasound guidance. The fetoscope will be advanced and the posterior urethral valves will be coagulated by ND:YAG laser. If urethra atresia was diagnosed, a vesico-amniotic shunting will be placed. Maternal anesthesia will be conducted by epidural anesthesia and fetal anesthesia will be conducted by injecting fentanyl (15 μg/Kg) and pancuronium (2 mg/Kg) under ultrasound guidance of a 22 gauge needle into fetal arm muscle.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vesico-amniotic shunt
Description: In this arm, all patients randomly selected for this treatment will undergo vesico-amniotic shunting under ultrasound guidance. Maternal anesthesia will be conducted by epidural anesthesia and fetal anesthesia will be conducted by injecting fentanyl (15 μg/Kg) and pancuronium (2 mg/Kg) under ultrasound guidance of a 22 gauge needle into fetal arm muscle.
Study: NCT03630484

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Expiratory Rib Cage Compression
Description: Compression was performed in 6 sets of 6 cycles, with 1 cycle interval. Ventilatory mode and parameters were maintained.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Compression + Ventilator Hyperinflation
Description: Mechanical ventilator hyperinflation was performed by increasing the inspiratory pressure to every 5 cmH2O until the total pressure reached 40 cmH2O, remaining the same. In Expiratory Rib Cage Compression associated with ventilator hyperinflation, thoracic compression maneuver was performed at the end of inspiration, at the exact moment of cycling.
Study: NCT04212858

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: zinc-finger protein 217 gene
Description: search for zinc-finger protein 217 gene in myeloma patients

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: zinc-finger protein 217 gene
Description: search for zinc-finger protein 217 gene in myeloma patients
Study: NCT01714817

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-188667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mycophenolate mofetil
Study: NCT02118675

Intervention type: OTHER
Intervention: Circumferences
Description: This test will measure the circumferences of your waist, hip, neck, arms, and legs and the lengths of your forearm, upper arm, thigh, and lower leg. The circumference measurements will be made by a trained observer using a calibrated tape measure and an automated circumference measurement device (KX-16). These measurements will be made in about 30 minutes.
Study: NCT01714817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching with BMS-188667
Study: NCT03440853

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TASCCI
Description: TASCCI is a stepped-care collaborative care approach of pharmaco- and/or behavioral-therapy for a 12 week period. The intervention will target 1 or more symptoms based on patients' report of clinical levels of each symptom and patient preference. A trained behavioral therapist will deliver weekly video conferencing sessions during dialysis treatment.

Intervention type: OTHER
Group type: OTHER
Intervention: Technology Delivered Health Education Intervention
Description: The Technology Delivered Health Education Intervention will deliver weekly video conferencing sessions to deliver online educational material from the National Kidney Foundation. These sessions will be delivered by a care coordinator.
Study: NCT00443235

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan/Prednisone/Velcade
Description: One cycle:~Melfalan, 9 mg/m2 v.o days 1 to 4 Prednisone, 60 mg/m2 v.o days 1 to 4 Velcade, 1,3 mg/m2 iv (days 1, 4, 8, 11, 22, 25, 29 and 32) Five cycles: Melfalán, 9 mg/m2 vo, days 1 to 4 Prednisone, 60 mg/m2 v.o days 1 to 4, Velcade,1,3 mg/ m2 iv (days 1, 8, 15 and 22)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide/Prednisone/Velcade
Description: One cycle:~Thalidomide,day 1 cycle 1 v.o (50 mg). If toxicity \< grade 2, dose will be increased to 100 mg on day 15 cycle 1 Prednisona, 60 mg/m2 vo, days 1 to 4, Velcade, 1,3 mg/ m2 iv (days 1, 4, 8, 11, 22, 25, 29 and 32)~Five cycles:~Thalidomide, 100 mg vo all days, Prednisone, 60 mg/m2 vo days 1 to 4, Velcade, 1,3 mg/ m2 iv (days 1, 8, 15 and 22)
Study: NCT03134313

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rainbow Adhesive Noninvasive R1 Pulse Oximeter Sensor
Study: NCT04026854

Intervention type: BEHAVIORAL
Intervention: Quality of live at work
Description: The judging criteria will be collected using two questionnaires: a questionnaire sent to the local referent of each center and a questionnaire for each nurse. Because the study is longitudinal (two collections of data), the questionnaires will be completed twice to twelve months apart by the same nurses.
Study: NCT01887587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN9708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT03137121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Olanzapine is used as an anti-emetic.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is a non-anti-emetic.
Study: NCT02670330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD-101-6.0 cream
Description: SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-6.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 6% and other excipients.
Study: NCT03593863

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Education (PE) programme
Description: The intervention consists of a 10-month (one academic year, September-June) physical activity programme delivered by PE teachers during regular Year-8 PE lessons. The Intervention involves roughly 20 minutes of prescribed activities per week.
Study: NCT03452891

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Methylcellulose
Description: Methylcellulose gel will be placed in a deep (6-9 mm) periodontal pocket.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin-Methylcellulose
Description: Simvastatin-Methylcellulose gel will be placed in a deep (6-9 mm) periodontal pocket.
Study: NCT02855450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhNGF
Description: Recombinant Human Nerve Growth Factor 180μg/ml (one 35 μl drop equals to 6.30 μg of rhNGF) reconstituted solution three times a day (TID) for 8 weeks of treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Ophthalmic Placebo solution of the same composition as the test product with the exception of rhNGF reconstituted solution times a day (TID) for 8 weeks of treatment.
Study: NCT01562366

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Topaz
Description: Radiofrequency micro debridement with Topaz will be used to treat the gluteal tendons following standard of care procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Iliotibial band release and trochanteric bursectomy
Description: Standard of Care: An iliotibial band release and trochanteric bursectomy will be performed.
Study: NCT02118675

Intervention type: OTHER
Intervention: Ultrasound
Description: An ultrasound is a procedure that uses sound waves to create a picture of an organ or soft tissue. This test measures the size of your tissue thicknesses for fat and skeletal muscle. For this procedure, you will be asked to raise your shirt, disrobe from the waist up, or change into a hospital gown and lie flat on your back on an examination table, or sit on a chair, or stand for measuring your leg dimensions. A gel will be spread on the ultrasound probe, and the probe will be applied directly to the skin on your arms, legs, and abdomen. You will feel slight pressure when the probe is applied. The entire procedure will take approximately 30 minutes.

Intervention type: OTHER
Intervention: Ultrasound
Description: An ultrasound is a procedure that uses sound waves to create a picture of an organ or soft tissue. This test measures the size of your tissue thicknesses for fat and skeletal muscle. For this procedure, you will be asked to raise your shirt, disrobe from the waist up, or change into a hospital gown and lie flat on your back on an examination table, or sit on a chair, or stand for measuring your leg dimensions. A gel will be spread on the ultrasound probe, and the probe will be applied directly to the skin on your arms, legs, and abdomen. You will feel slight pressure when the probe is applied. The entire procedure will take approximately 30 minutes.
Study: NCT04206527

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training of AHSAs on PCC for FP
Description: ASHAs provided with training on FP methods and counseling plus PCC for FP

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced FP training
Description: Participation in an enhanced FP training including PCC
Study: NCT02708927

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical evaluation
Description: • Clinical assessment : Expanded Disability Status Scale (EDSS), ambulation test. Medications will be recorded.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive evaluation
Description: • Neuropsychological, psychological, social and social cognitive evaluation
Study: NCT00188266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatinum combined with infusional fluorouracil (5 FU)
Description: Continuous 5FU via intravenous PICC line + 4 doses of Cisplatin every 2 weeks
Study: NCT00780702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Airipiprazole
Description: Participants receive aripiprazole (orally, up to 15 mg/day) plus standard methadone maintenance (daily oral methadone and weekly individual counseling).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants receive identical capsules containing no active medication plus standard methadone maintenance (daily oral methadone and weekly individual counseling).
Study: NCT00731848

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: pomegranate liquid extract
Description: Pomegranate liquid extract, 8 oz per day, for 52 weeks
Study: NCT03707964

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Crisis Resource Management Skill Training
Description: Focused crisis resource management training which targets at the cognitive skills needed to monitor and challenge a superior's decision.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard ACLS Training
Description: Standard didactic interactive session on Advanced Cardiac Life Support (ACLS) principles.
Study: NCT01519063

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naltrexone and memantine first
Description: Naltrexone 50mg memantine 20mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone and memantine first
Description: Naltrexone 50mg memantine 20mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naltrexone and Placebo first
Description: Naltrexone 50 mg Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone and Placebo first
Description: Naltrexone 50 mg Placebo
Study: NCT06123910

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Colostrum bovine
Description: Colostrum bovine supplements, 25 kcal per portion, containing 0.25 g fats, 2.0 g CHO and 3 g protein. Lactose reduced.
Study: NCT02708927

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive evaluation
Description: • Neuropsychological, psychological, social and social cognitive evaluation
Study: NCT04578496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afamelanotide
Study: NCT06123910

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dairy comercial product. 25 kcal per portion, 1.3 g fats, 1.95 CHO and 1.3 protein. Lactose based.
Study: NCT02011867

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cork Electrode
Study: NCT02209311

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral mucosa biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sinus lift with implantation of tissue engineered construction

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental implant
Study: NCT01362946

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reward-Emphasized Treatment
Description: Intensive behavioral treatment delivered in a summer camp setting, with reward components emphasized and punishment components de-emphasized

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: Intensive behavioral treatment delivered in a summer camp setting, with rewards and punishment equally emphasized.
Study: NCT03300752

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BREATHE Intervention
Description: PCPs randomized to BREATHE will receive the tablet which, when the screen is advanced by the PCP, will prompt the PCP through a 7-minute, 4-step brief intervention tailored to respond to the patient's specific beliefs, and shared decision-making discussion of asthma control status and treatment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Intervention
Description: PCP will provide discussion of healthy lifestyles.
Study: NCT02871193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: ultrasound-guided thoracic paravertebral nerve block (TPVB) with 0.5% ropivacaine 20ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: ultrasound-guided thoracic paravertebral nerve block (TPVB) with 0.5% ropivacaine 20ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: ultrasound-guided thoracic paravertebral nerve block (TPVB) with 0.5% ropivacaine 20ml and dexamethasone 5 mg

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: saline
Description: ultrasound-guided thoracic paravertebral nerve block (TPVB) with 0.9% saline 20ml
Study: NCT02909842

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Drinking fermented milk
Description: Drinking fermented milk containing Lactobacillus paracasei (IMULUS)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Acidified placebo milk with similar physical characteristics to the yoghurt drink

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Seasonal Influenza Vaccine (H1N1, H3N2, PhuB)
Description: Intramuscular injection of a single shot of influenza vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal Influenza Vaccine (H1N1, H3N2, PhuB)
Description: Intramuscular injection of a single shot of influenza vaccine
Study: NCT03309592

Intervention type: DRUG
Group type: OTHER
Intervention: Ambrisentan Pill
Description: Will be administered as stated in Arm/Group Descriptions

Intervention type: DRUG
Group type: OTHER
Intervention: Tadalafil Pill
Description: Will be administered as stated in Arm/Group Descriptions
Study: NCT00878631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hypertonic saline mixed with dextran
Description: a single dose 250 ml of 7.5% hypertonic saline in 6% dextran 70 is given within 4 hours from the time of the accident

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: 250 ccs of normal saline infused within 4 hours of the accident
Study: NCT04433624

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group (B)
Description: Group (B) (n=15): will receive The bilateral ESP blocks were performed by injecting 40 mL of 0.25% bupivacaine (20 mL into each side) into the fascial plane between the deep surface of the erector spinae muscle and the transverse processes of the lumbar vertebrae

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group (B)
Description: Group (B) (n=15): will receive The bilateral ESP blocks were performed by injecting 40 mL of 0.25% bupivacaine (20 mL into each side) into the fascial plane between the deep surface of the erector spinae muscle and the transverse processes of the lumbar vertebrae
Study: NCT01374763

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Prolonged-release oxycodone 10-30 mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged-release oxycodone/naloxone
Description: Prolonged-release oxycodone/naloxone 10-30 mg twice daily
Study: NCT01832012

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multimedia
Description: AHA specific BLS refresher video, 7 minutes in length.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimedia
Description: AHA specific BLS refresher video, 7 minutes in length.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hands-on practice
Description: Hands-on BLS CPR practice on a Laerdal BLS manikin.
Study: NCT03136133

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active protein drink
Description: Fish protein from cod to be used for man after Heavy excercise to restitute

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Active protein drink
Description: Fish protein from cod to be used for man after Heavy excercise to restitute
Study: NCT01689402

Intervention type: DEVICE
Intervention: MRI Scan with the specified sequences below:
Description: Standard sequences: Axial T2, axial DWI, Sagittal T1, T2 flair og axial GRE-sequence.~Susceptibility weighted imaging (SWI)~Chemical Shift Imaging (CSI) multivoxel spectroscopi~Post contrast 3D box reconstruction
Study: NCT03769324

Intervention type: DIAGNOSTIC_TEST
Intervention: Osmolarity Test
Description: Osmolarity Test

Intervention type: DIAGNOSTIC_TEST
Intervention: Osmolarity Test
Description: Osmolarity Test
Study: NCT03863067

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epiduroscopy
Description: Using epiduroscopy to treat the ligamentum flavum hypertrophy with Resaflex ,an instrument with Quantum Molecular Resonance for tissue coablation.
Study: NCT00518921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capadenoson (BAY 68-4986)
Description: 1mg Capadenoson, double dummy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capadenoson (BAY 68-4986)
Description: 2mg Capadenoson, double dummy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capadenoson (BAY 68-4986)
Description: 4mg Capadenoson, double dummy
Study: NCT04916145

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAT-008
Description: SAT-008 is a digital device containing several types of activities related to the immune function of adults.
Study: NCT00518921

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, double dummy